NCT06644534View on ClinicalTrials.gov

A Study to Assess TTI-0102 vs Placebo in MELAS Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 12, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2026

Conditions
MELAS SyndromeMitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)
Interventions
DRUG

TTI-0102

(cysteamine-pantetheine disulfide)

DRUG

Placebo

Pearlitol® 100 SD (mannitol)

Trial Locations (2)

49100

RECRUITING

Angers University Hospital Center (CHU Angers), Angers

6500 HB

RECRUITING

Radboud University Medical Center, Nijmegen

All Listed Sponsors
lead

Thiogenesis Therapeutics, Inc.

INDUSTRY